Hi All,
just saw an interesting post (https://www.iqwig.de/en/press/press-releases/press-releases/adaptive-pathways-ema-still-leaves-open-questions-unanswered.7492.html) from IQWIG, that speaks to the difficulties to get even a clinical effectiveness assessment under one roof as always proposed by various stakeholders. Clearly the RWE bit is still an open book in many ways but a topic to be tackled on various fronts in order to make true value based pricing a reality.
Cheers
Ulf
Subscribe to:
Posts (Atom)
Blog Archive
-
►
2008
(75)
- January (14)
- February (7)
- March (10)
- April (6)
- May (4)
- June (3)
- July (7)
- August (3)
- September (4)
- October (9)
- November (5)
- December (3)
-
►
2009
(41)
- January (8)
- February (4)
- March (4)
- April (4)
- May (1)
- June (5)
- July (2)
- August (3)
- September (3)
- October (2)
- November (2)
- December (3)
-
►
2010
(31)
- January (1)
- February (8)
- March (2)
- May (2)
- June (2)
- July (3)
- August (2)
- September (4)
- October (3)
- November (2)
- December (2)
-
►
2011
(29)
- January (6)
- February (3)
- March (1)
- May (2)
- June (4)
- July (3)
- August (2)
- September (4)
- October (3)
- November (1)
-
►
2012
(16)
- January (1)
- February (4)
- May (3)
- July (2)
- August (1)
- October (1)
- November (1)
- December (3)
